Continuous Release Dopamine Agonists — Competitive Intelligence Brief

Continuous Release Dopamine Agonists (Continuous Release Dopamine Agonists) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine agonist. Area: Neurology.

phase 3 Dopamine agonist Dopamine receptors (D1, D2, D3, D4, D5) Neurology Small molecule

Target snapshot

Continuous Release Dopamine Agonists (Continuous Release Dopamine Agonists) — University of Toledo. Continuous release dopamine agonists stimulate dopamine receptors in the brain to provide sustained therapeutic effects for movement and neurological disorders.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Continuous Release Dopamine Agonists TARGET	Continuous Release Dopamine Agonists	University of Toledo	phase 3	Dopamine agonist	Dopamine receptors (D1, D2, D3, D4, D5)
Neupro	ROTIGOTINE	UCB	marketed	Nonergot Dopamine Agonist [EPC]	dopamine receptors	2007-01-01
DC	DC	Gary Archer Ph.D.	marketed	dopamine agonist	dopamine receptor
Dopamine Agonists	Dopamine Agonists	Leiden University Medical Center	marketed	Dopamine agonist	Dopamine receptors (D1-D5)
ROP+L-Dopa	ROP+L-Dopa	GlaxoSmithKline	marketed	Dopamine agonist + Levodopa combination	Dopamine receptors (D2/D3); Dopamine pathway
Dopamine Agent	Dopamine Agent	I.R.C.C.S. Fondazione Santa Lucia	marketed	Dopamine agonist or dopamine enhancer	Dopamine receptors (D1-D5) or dopamine transporter
ropinirole/L-dopa	ropinirole/L-dopa	GlaxoSmithKline	marketed	Dopamine agonist and dopamine precursor combination	Dopamine D2/D3 receptors (ropinirole); dopamine synthesis pathway (L-dopa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine agonist class)

1. Sumitomo Pharma America, Inc. · 2 drugs in this class
2. University Hospital, Toulouse · 2 drugs in this class
3. Rennes University Hospital · 2 drugs in this class
4. Britannia Pharmaceuticals Ltd. · 1 drug in this class
5. Desitin Arzneimittel GmbH · 1 drug in this class
6. GlaxoSmithKline · 1 drug in this class
7. Intec Pharma Ltd. · 1 drug in this class
8. Leiden University Medical Center · 1 drug in this class
9. Ludwig-Maximilians - University of Munich · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class